Managing hypertension in type 2 diabetes mellitus

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 30, Issue 3, 2016, Pages 445-454

  Horr, Samuel ^a   Nissen, Steven ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

diabetes mellitus; hypertension; pharmacology

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRACTICE GUIDELINE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTOLIC BLOOD PRESSURE; COMPLICATION;

ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION;

EID: 84990215961     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2016.06.001     Document Type: Review

References (75)

1. Nwankwo, T., Yoon, S.S., Burt, V., et al. Hypertension among adults in the united states: national health and nutrition examination survey, 2011–2012. 2013, NCHS Data Brief, 1–8.
2. [2] World health organization, Global status report on noncommunicable disease 2010. Geneva., 2011, World Health Organization.
3. [3] Lim, S.S., Vos, T., Flaxman, A.D., et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet 380 (2012), 2224–2260.
4. [4] Major, S.G., Blood pressure in diabetes mellitus: a statistical study. Arch Int Med 44 (1929), 797–812.
5. [5] Gillespie, C.D., Hurvitz, K.A., Prevalence of hypertension and controlled hypertension – united states, 2007–2010. MMWR Surveill Summ 62:Suppl. 3 (2013), 144–148.
6. [6] Colosia, A.D., Palencia, R., Khan, S., Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes Metab Syndr Obes 6 (2013), 327–338.
7. [7] Hypertension in diabetes study (HDS) I: prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 11 (1993), 309–317.
8. [8] Haffner, S.M., Miettinen, H., Gaskill, S.P., et al. Metabolic precursors of hypertension. The san antonio heart study. Arch Intern Med 156 (1996), 1994–2001.
9. [9] Gress, T.W., Nieto, F.J., Shahar, E., et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis risk in communities study. N Engl J Med 342 (2000), 905–912.
10. [10] International Diabetes Federation, IDF diabetes atlas. 7th ed., 2015, International Diabetes Federation, Brussels.
11. [11] Lewington, S., Clarke, R., Qizilbash, N., et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002), 1903–1913.
12. [12] Adler, A.I., Stratton, I.M., Neil, H.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321 (2000), 412–419.
13. [13] Assmann, G., Schulte, H., The prospective cardiovascular munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 116 (1988), 1713–1724.
14. [14] Haffner, S.M., Lehto, S., Ronnemaa, T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med 339 (1998), 229–234.
15. [15] Ferrannini, E., Buzzigoli, G., Bonadonna, R., et al. Insulin resistance in essential hypertension. N Engl J Med 317 (1987), 350–357.
16. [16] Natali, A., Quinones Galvan, A., Arzilli, F., et al. Renovascular hypertension and insulin sensitivity. Eur J Clin Invest 26 (1996), 556–563.
17. [17] Lago, R.M., Singh, P.P., Nesto, R.W., Diabetes and hypertension. Nat Clin Pract Endocrinol Metab, 3, 2007, 667.
18. Emdin, C.A., Rahimi, K., Neal, B., et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313 (2015), 603–615.
19. Patel, A., MacMahon, S., Chalmers, J., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007), 829–840.
20. Turnbull, F., Neal, B., Algert, C., et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 165 (2005), 1410–1419.
21. [21] Hansson, L., Zanchetti, A., Carruthers, S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Hot study group Lancet 351 (1998), 1755–1762.
22. [22] Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK prospective diabetes study group BMJ 317 (1998), 703–713.
23. [23] Curb, J.D., Pressel, S.L., Cutler, J.A., et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. J Am Med Assoc 276 (1996), 1886–1892.
24. [24] Staessen, J., Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension (vol 350, pg 757, 1997). Lancet, 350, 1997, 1636.
25. Cardiovascular disease and risk management. Diabetes Care 38 (2015), S49–S57.
26. Cushman, W.C., Evans, G.W., Byington, R.P., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1575–1585.
27. [27] A randomized trial of intensive versus standard blood-pressure control. The SPRINT Research Group N Engl J Med 373 (2015), 2103–2116.
28. [28] The fifth report of the joint national committee on detection, evaluation, and treatment of high blood pressure (jnc v). Arch Intern Med 153 (1993), 154–183.
29. [29] The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157 (1997), 2413–2446.
30. [30] Standards of medical care for patients with diabetes mellitus. Diabetes Care 25 (2002), 213–229.
31. [31] Chobanian, A.V., Bakris, G.L., Black, H.R., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the jnc 7 report. JAMA 289 (2003), 2560–2572.
32. [32] Mancia, G., De Backer, G., Dominiczak, A., et al. ESH/ESC 2007 guidelines for the management of arterial hypertension. Rev Esp Cardiol 60:968 (2007), e961–e994.
33. Taylor, J., 2013 ESH/ESC guidelines for the management of arterial hypertension. Eur Heart J 34 (2013), 2108–2109.
34. [34] Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the hope study and micro-hope substudy. Heart outcomes prevention evaluation study investigators Lancet 355 (2000), 253–259.
35. [35] Pfeffer, M.A., Swedberg, K., Granger, C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the charm-overall programme. Lancet 362 (2003), 759–766.
36. [36] Parving, H.H., Lehnert, H., Brochner-Mortensen, J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001), 870–878.
37. [37] Mogensen, C.E., Neldam, S., Tikkanen, I., et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (calm) study. BMJ 321 (2000), 1440–1444.
38. [38] Lebovitz, H.E., Wiegmann, T.B., Cnaan, A., et al. Renal protective effects of enalapril in hypertensive niddm: role of baseline albuminuria. Kidney Int Suppl 45 (1994), S150–S155.
39. [39] Brenner, B.M., Cooper, M.E., de Zeeuw, D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001), 861–869.
40. [40] Lewis, E.J., Hunsicker, L.G., Clarke, W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001), 851–860.
41. [41] Lindholm, L.H., Ibsen, H., Dahlof, B., et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002), 1004–1010.
42. [42] Berl, T., Hunsicker, L.G., Lewis, J.B., et al. Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138 (2003), 542–549.
43. [43] Ruggenenti, P., Fassi, A., Ilieva, A.P., et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351 (2004), 1941–1951.
44. [44] Wright, J.T. Jr., Dunn, J.K., Cutler, J.A., et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 293 (2005), 1595–1608.
45. [45] Weir, M.R., Gray, J.M., Paster, R., et al. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The trandolapril multicenter study group Hypertension 26 (1995), 124–130.
46. [46] Middlemost, S.J., Tager, R., Davis, J., et al. Effectiveness of enalapril in combination with low-dose hydrochlorothiazide versus enalapril alone for mild to moderate systemic hypertension in black patients. Am J Cardiol 73 (1994), 1092–1097.
47. [47] Weir, M.R., Ferdinand, K.C., Flack, J.M., et al. A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. Hypertension 46 (2005), 508–513.
48. [48] Alkharouf, J., Nalinikumari, K., Corry, D., et al. Long-term effects of the angiotensin converting enzyme inhibitor captopril on metabolic control in non-insulin-dependent diabetes mellitus. Am J Hypertens 6 (1993), 337–343.
49. [49] Bosch, J., Yusuf, S., Gerstein, H.C., et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 355 (2006), 1551–1562.
50. [50] McMurray, J.J., Holman, R.R., Haffner, S.M., et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362 (2010), 1477–1490.
51. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288 (2002), 2981–2997.
52. [52] Whelton, P.K., Barzilay, J., Cushman, W.C., et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: antihypertensive and lipid-lowering treatment to prevent heart attack trial (allhat). Arch Intern Med 165 (2005), 1401–1409.
53. [53] Elliott, W.J., Meyer, P.M., Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369 (2007), 201–207.
54. [54] Barzilay, J.I., Davis, B.R., Pressel, S.L., et al. Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the allhat diabetes extension study. Circ Cardiovasc Qual Outcomes 5 (2012), 153–162.
55. [55] Grossman, E., Messerli, F.H., Are calcium antagonists beneficial in diabetic patients with hypertension?. Am J Med 116 (2004), 44–49.
56. [56] Tuomilehto, J., Rastenyte, D., Birkenhager, W.H., et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic hypertension in europe trial investigators N Engl J Med 340 (1999), 677–684.
57. [57] Birkenhager, W.H., Staessen, J.A., Treatment of diabetic patients with hypertension. Curr Hypertens Rep 1 (1999), 225–231.
58. [58] Dahlof, B., Sever, P.S., Poulter, N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the anglo-scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 (2005), 895–906.
59. [59] Estacio, R.O., Jeffers, B.W., Hiatt, W.R., et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338 (1998), 645–652.
60. [60] Tatti, P., Pahor, M., Byington, R.P., et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (facet) in patients with hypertension and niddm. Diabetes Care 21 (1998), 597–603.
61. [61] Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group BMJ 317 (1998), 713–720.
62. [62] Messerli, F.H., Bangalore, S., Julius, S., Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 117 (2008), 2706–2715 discussion 2715.
63. [63] Bakris, G.L., Fonseca, V., Katholi, R.E., et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292 (2004), 2227–2236.
64. [64] Giugliano, D., Acampora, R., Marfella, R., et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 126 (1997), 955–959.
65. Jamerson, K., Weber, M.A., Bakris, G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359 (2008), 2417–2428.
66. [66] Weber, M.A., Bakris, G.L., Jamerson, K., et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 56 (2010), 77–85.
67. Yusuf, S., Teo, K.K., Pogue, J., et al. Investigators O. Telmisartan, ramipril, or both in patients at high risk for vascular events. New Engl J Med 358 (2008), 1547–1559.
68. [68] Fried, L.F., Emanuele, N., Zhang, J.H., et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369 (2013), 1892–1903.
69. [69] Chapman, N., Dobson, J., Wilson, S., et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49 (2007), 839–845.
70. [70] Calhoun, D.A., White, W.B., Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2 (2008), 462–468.
71. [71] Vaclavik, J., Sedlak, R., Plachy, M., et al. Addition of spironolactone in patients with resistant arterial hypertension (aspirant): a randomized, double-blind, placebo-controlled trial. Hypertension 57 (2011), 1069–1075.
72. [72] Williams, B., MacDonald, T.M., Morant, S., et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (pathway-2): a randomised, double-blind, crossover trial. Lancet 386:10008 (2015), 2059–2068.
73. [73] Oxlund, C.S., Henriksen, J.E., Tarnow, L., et al. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 31 (2013), 2094–2102.
74. [74] Tikkanen, I., Narko, K., Zeller, C., et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 38 (2015), 420–428.
75. [75] Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:22 (2015), 2117–2128.